Early integration of palliative care facilitates the discontinuation of anticancer treatment in women with advanced breast or gynecologic cancers

Improvement in symptom burden within one day after palliative care consultation in a cohort of gynecologic oncology inpatients

“…Our data suggest that patient with high symptom burden may be an appropriate group to consider for standardized palliative care consultation. Our data also add to the growing body of literature supporting the benefits of early integration of palliative care, both earlier rather than later in the disease course [32,[38][39][40] and earlier rather than later in the course of hospitalizations [41][42]. In our cohort, 72% of palliative care consultations happened the day of or the day after admission.…”

Early Palliative Care and Its Role in Oncology: A Qualitative Study

“…Of these, the model that has received the greatest attention and endorsement, in particular, for cancer centers, is simultaneous care by specialized palliative care in an outpatient setting [13,15,16]. This model was used in two randomized controlled trials (RCTs) demonstrating the benefits of EPC and was also supported by the results of nonrandomized prospective and retrospective studies [17][18][19]. Although this model has been examined qualitatively by a review of the electronic medical records of patients receiving EPC [20] and by interviewing oncologists and palliative care physicians [21,22], the opinions of patients and caregivers regarding this model of care have not been sought.…”

Integrated care in cancer: What is it, how is it used and where are the gaps? A textual narrative literature synthesis

“…38 publications were included in the review (Table ). Papers originated from Australia (Le et al., ), the UK (Gage et al., ; Letton, Cheung, & Nordin, ; Murchie, Hannaford, Wyke, Nicolson, & Campbell, ; Selwood, ; Sharpe et al., ; Walker, Hansen, et al., ; Walker, Walker, et al., ), Europe (Ben‐Arye, Schiff, Raz, Samuels, & Lavie, ; Ben‐Arye et al., ; Camps et al., ; Colombet et al., ; Coriat et al., ; Gaertner et al., ; Hanan et al., ; van Hoeve, de Munck, Otter, de Vries, & Siesling, ; Ouwens, Hermens, et al., ; Popper‐Giveon, Schiff, & Ben‐Arye, ; Popper‐Giveon, Schiff, Hatem, Samuels, & Ben‐Arye, ; Prades & Borras, ; Pugliese et al., ; Savio et al., ), North America (Bekelman et al., ; Bjegovich‐Weidman et al., ; Brazier, Cooke, & Moravan, ; Bruera et al., ; Chubak et al., ; Delaney et al., ; Douglas & Daly, ; Hofstatter, Saadati, Russell, & III Russell, ; Hui et al., ; Hydeman, ; Judge Santacroce, Asmus, Kadan‐Lottick, & Grey, ; Kligler et al., ; Marshall et al., ; Prince‐Paul, Burant, Saltzman, Teston, & Matthews, ; Tam et al., ; Temel et al., ) and South America (Rugno, Paiva, & Paiva, ).…”

“…79% (30/38) of papers had a focus on horizontal integration, improving the coordination of cancer care within the specialist or tertiary setting. Three main approaches were utilised within this group of studies: expansion of multidisciplinary care team (Delaney et al., ; Douglas & Daly, ; Judge Santacroce et al., ; Prince‐Paul et al., ; Pugliese et al., ; Savio et al., ; Sharpe et al., ; Walker, Hansen, et al., ; Walker, Walker, et al., ), enhancing the functioning of the multidisciplinary care team (Bekelman et al., ; Bjegovich‐Weidman et al., ; Coriat et al., ; Letton et al., ; Marshall et al., ; Ouwens, Hermens, et al., ; Selwood, ), and facilitating coordination between specialist care teams such as palliative care (Colombet et al., ; Gaertner et al., ; Hui et al., ; Hydeman, ; Le et al., ; Rugno et al., ; Temel et al., ), complementary medicine(Ben‐Arye et al., , ; Gage et al., ; Kligler et al., ), and other medical specialties. Organisational level integration was addressed in two studies examining the impact of colocation of care providers treating prostate cancer (Bruera et al., ; Hofstatter et al., ).…”

“…Half of the papers (19/38) were conducted in populations that had a specific cancer type including prostate (Bekelman et al., ), lung (Bjegovich‐Weidman et al., ; Chubak et al., ; Douglas & Daly, ; Le et al., ; Temel et al., ; Walker, Hansen, et al., ), breast (Chubak et al., ; van Hoeve et al., ; Rugno et al., ; Tam et al., ), colorectal (Chubak et al., ; Douglas & Daly, ; Marshall et al., ; Pugliese et al., ), gynaecological (Douglas & Daly, ; Letton et al., ; Rugno et al., ) glioma (Delaney et al., ), melanoma (Murchie et al., )and head and neck (Ouwens, Hermens, et al., ) or were age group specific (Judge Santacroce et al., ; Savio et al., ; Selwood, ). Almost all (34/38) papers addressed the diagnosis and treatment phase, ten of which were not phase‐specific (Brazier et al., ; Bruera et al., ; Camps et al., ; Gage et al., ; Hanan et al., ; Popper‐Giveon et al., , ; Sharpe et al., ; Tam et al., ; Walker, Hansen, et al., ; Walker, Walker, et al., ).…”